[go: up one dir, main page]

NL2009995A - Compositions. - Google Patents

Compositions. Download PDF

Info

Publication number
NL2009995A
NL2009995A NL2009995A NL2009995A NL2009995A NL 2009995 A NL2009995 A NL 2009995A NL 2009995 A NL2009995 A NL 2009995A NL 2009995 A NL2009995 A NL 2009995A NL 2009995 A NL2009995 A NL 2009995A
Authority
NL
Netherlands
Prior art keywords
composition
capsule
cetilistat
formulation
weight
Prior art date
Application number
NL2009995A
Other languages
English (en)
Other versions
NL2009995C2 (en
Inventor
John Robert Bloor
Christopher Robert Dunk
Richard Michael John Palmer
Original Assignee
Norgine Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1122213.0A external-priority patent/GB201122213D0/en
Priority claimed from GBGB1203082.1A external-priority patent/GB201203082D0/en
Application filed by Norgine Bv filed Critical Norgine Bv
Publication of NL2009995A publication Critical patent/NL2009995A/en
Application granted granted Critical
Publication of NL2009995C2 publication Critical patent/NL2009995C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/24—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in positions 2 and 4
    • C07D265/26—Two oxygen atoms, e.g. isatoic anhydride
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/25—Silicon; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A61K8/463—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfuric acid derivatives, e.g. sodium lauryl sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/731—Cellulose; Quaternized cellulose derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/732—Starch; Amylose; Amylopectin; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/30—Characterized by the absence of a particular group of ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manipulation Of Pulses (AREA)
  • Logic Circuits (AREA)

Claims (20)

1. Een samenstelling omvattende een mengsel van bestanddelen (i)-(v): (i) cetilistat; en (ii) microkristallijn cellulose; en (iii) natriumlaurylsulfaat; en (iv) natriumzetmeelglycolaat; en (v) talk.
2. Samenstelling volgens conclusie 1, welke samenstelling geen polyvinylpyrrolidon bevat.
3. Samenstelling volgens conclusie 1 of conclusie 2 bestaande uit een mengsel van bestanddelen (i)-(v): (i) cetilistat; en (ii) microkristallijn cellulose; en (iii) natriumlaurylsulfaat; en (iv) natriumzetmeelglycolaat; en (v) talk.
4. Een capsule bevattende een samenstelling volgens één der conclusies 1-3.
5. Capsule volgens conclusie 4 bevattende een samenstelling bestaande uit een mengsel van bestanddelen (i)-(v): (i) cetilistat; en (ii) microkristallijn cellulose; en (iii) natriumlaurylsulfaat; en (iv) natriumzetmeelglycolaat; en (v) talk.
6. Capsule volgens conclusie 4 of conclusie 5, waarin de capsule 10 mg, 40 mg, 50 mg, 60 mg, 80 mg, 120 mg, of 150 mg cetilistat bevat.
7. Capsule volgens één der conclusies 4-6, waarin de capsule een harde capsule is.
8. Een kit omvattende een verpakking welke een aantal capsules bevat, waarin elke capsule een capsule volgens één der conclusies 4-7 is.
9. Kit volgens conclusie 8, waarin de verpakking een blister, blisterverpakking, buis, pot, fles, zak, wikkel of een andere houder is.
10. Een samenstelling volgens één der conclusies 1-3 of een capsule volgens één der conclusies 4-7, voor gebruik in gewichtsbeheersing.
11. Samenstelling of capsule volgens conclusie 10, voor het helpen van een patiënt bij het beheersen van het gewicht van de patiënt.
12. Samenstelling of capsule volgens conclusie 10 of conclusie 11, voor gebruik in mensen welke een BMI hoger dan 18.5 kg/m2 hebben.
13. Een samenstelling volgens één der conclusies 1-3 of capsule volgens één der conclusies 4-7, voor gebruik bij gewichtsverlies.
14. Samenstelling of capsule volgens conclusie 13, voor het bevorderen van gewichtsverlies.
15. Samenstelling of capsule volgens conclusie 14, voor het helpen van een te zware of zwaarlijvige patiënt met het verliezen van gewicht.
16. Samenstelling of capsule volgens één der conclusies 13 to 15, voor gebruik in mensen met een BMI hoger dan 18.5 kg/m2.
17. Een capsule voor gebruik in gewichtsbeheersing, waarin de capsule een samenstelling bevat welke bestaat uit een mengsel van bestanddelen (i)-(v): (i) cetilistat; en (ii) microkristallijn cellulose; en (iii) natriumlaurylsulfaat; en (iv) natriumzetmeelglycolaat; en (v) talk.
18. Een capsule voor gebruik bij gewichtsverlies, waarin de capsule een samenstelling bevat welke bestaat uit een mengsel van bestanddelen (i)-(v): (i) cetilistat; en (ii) microkristallijn cellulose; en (iii) natriumlaurylsulfaat; en (iv) natriumzetmeelglycolaat; en (v) talk.
19. Een samenstelling in hoofdzaak zoals hierin beschreven onder verwijzing naar voorbeeld 1.
20. Een capsule in hoofdzaak zoals hierin beschreven onder verwijzing naar voorbeeld 1.
NL2009995A 2011-12-23 2012-12-17 Compositions. NL2009995C2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1122213.0A GB201122213D0 (en) 2011-12-23 2011-12-23 Compositions
GB201122213 2011-12-23
GBGB1203082.1A GB201203082D0 (en) 2012-02-22 2012-02-22 Compositions
GB201203082 2012-02-22

Publications (2)

Publication Number Publication Date
NL2009995A true NL2009995A (en) 2013-06-26
NL2009995C2 NL2009995C2 (en) 2013-09-18

Family

ID=47560448

Family Applications (1)

Application Number Title Priority Date Filing Date
NL2009995A NL2009995C2 (en) 2011-12-23 2012-12-17 Compositions.

Country Status (8)

Country Link
AU (1) AU2012101841A4 (nl)
DK (1) DK201200198Y4 (nl)
ES (1) ES2417408B1 (nl)
FI (1) FI10194U1 (nl)
FR (1) FR2984745B3 (nl)
IE (1) IES86183B2 (nl)
IT (1) ITTO20121118A1 (nl)
NL (1) NL2009995C2 (nl)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
AR022204A1 (es) * 1999-01-08 2002-09-04 Norgine Bv Compuesto, proceso para su preparacion, composicion farmaceutica y producto comestible que lo comprende.
PT1897558E (pt) * 2005-06-09 2013-11-06 Norgine Bv Preparação sólida de 2-hexadeciloxi-6-metil-4h-3,1- benzoxazin-4-ona
JP2010254623A (ja) * 2009-04-24 2010-11-11 Takeda Chem Ind Ltd ベンゾオキサジノン化合物の結晶

Also Published As

Publication number Publication date
IES20120556A2 (en) 2013-05-08
NL2009995C2 (en) 2013-09-18
ES2417408A2 (es) 2013-08-07
FR2984745A3 (fr) 2013-06-28
DK201200198Y4 (da) 2018-09-17
FI10194U1 (fi) 2013-08-20
ES2417408R1 (es) 2013-10-15
ITTO20121118A1 (it) 2013-06-24
FR2984745B3 (fr) 2017-12-22
DK201200198U1 (en) 2013-04-12
IES86183B2 (en) 2013-05-08
AU2012101841A4 (en) 2013-01-17
ES2417408B1 (es) 2014-11-26

Similar Documents

Publication Publication Date Title
US20100081715A1 (en) Formulation Comprising Fenofibric Acid, A Physiologically Acceptable Salt or Derivative Thereof
IL187420A (en) Pharmaceutical dosage form containing wildglyliptin and hydroxypropyl methylcellulose, a process for its preparation and use in the preparation of drugs to inhibit the activity of dipeptidyl peptidase IV
US9060979B2 (en) Antidepressant
CN103313711A (zh) 在纳曲酮疗法中增加药物生物可利用性
EP1933815A2 (en) Pharmaceutical packaging of an oral dosage combination
NL2009995C2 (en) Compositions.
CA2870813A1 (en) Dietary fiber compositions for the treatment of metabolic disease
DE202012104963U1 (de) Cetilistat aufweisende Zusammensetzungen
WO2013092786A1 (en) Compositions comprising cetilistat
IES86183Y1 (en) Compositions comprising cetilistat
IE20120556U1 (en) Compositions comprising cetilistat
CN106822097A (zh) 一种用于减肥的含奥利司他的药物组合物
WO2010104175A1 (ja) 経口用組成物
RU2552926C1 (ru) Фармацевтическая комбинация для лечения и/или предупреждения нарушений, связанных с избыточным весом и/или ожирением, и способ лечения на ее основе
JP2023529001A (ja) 結晶形のラベキシモドを含む経口製剤
US20080107715A1 (en) Pharmaceutical containing food compositions and uses thereof
CN106955357B (zh) 一种用于宠物减肥的复方奥利司他组合物制剂及其应用
AT13775U1 (de) Pharmazeutische Zusammensetzung
EP1832285A1 (en) Formulation comprising fenofibric acid or a physiologically acceptable salt thereof
JPH0640936A (ja) 高脂血症の予防及び治療剤
Susp sodium polystyrene sulfonate (C)(G)
CN102793716A (zh) 脂族胺聚合物的用途及其药物组合物和制备方法
NZ574317A (en) Improved animal treatment
CN106880644A (zh) 一种由考来维仑制成的用于治疗获得性肥胖的药物组合物
MX2008004895A (en) Pharmaceutical packaging of an oral dosage combination

Legal Events

Date Code Title Description
MM Lapsed because of non-payment of the annual fee

Effective date: 20200101